Initial investment $217M at Denali Therapeutics
Having received an initial investment commitment of 217 million dollars, Denali Therapeutics, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases launched its services. Among the founding investors of the company are Fidelity Biosciences, ARCH Venture Partners, Flagship Ventures and the Alaska Permanent Fund. Denali Therapeutics is based on the collaboration of world-class scientists, industry experts and investors. Recent scientific insights into the genetic causes and biological processes underlying neurodegenerative disease, together with new medicine tools, offer an unprecedented opportunity to discover and develop effective medicines for Alzheimer’s disease, Parkinson’s disease, ALS etc.